ReviewApplied microbiology and biotechnology2015
Pseudomonas putida-a versatile host for the production of natural products.
Review in Applied microbiology and biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 289 citations in OpenAlex.
- High-level prodigiosin production inSynthetic and systems biotechnology · 2026Article
- Comparative analysis of precursor supply and pathway reinforcement strategies for shikimic acid biosynthesis in Pseudomonas putida.Microbial cell factories · 2026Article
- Biosynthesis of medium-chain length polyhydroxyalkanoates from pre-treated food wastewater.Biotechnology for biofuels and bioproducts · 2026Article
- Genome editing of phylogenetically distinct bacteria using cross-species retron-mediated recombineering.Nature biotechnology · 2026Article
- Multi-strain analysis ofmSystems · 2026Article
- Advances in microbial mevalonolactone production: from fermentative mevalonate accumulation to downstream lactonization.Engineering microbiology · 2026Review
- Rhizosphere microbiome engineering with PGPR to combat soil-mediated climate change.Frontiers in microbiology · 2026Review
- Strategic selection of microbial cell factories for sustainable and application-specific terpenoid production.Frontiers in bioengineering and biotechnology · 2026Review
- A Reporter System for Assessment of Transcription from Divergently Oriented Promoters inACS synthetic biology · 2025Article
- Multi-strain Analysis ofbioRxiv : the preprint server for biology · 2025Article
- Engineering of 1,4-Butanediol and Adipic Acid Metabolism in Pseudomonas taiwanensis for Upcycling to Aromatic Compounds.Microbial biotechnology · 2025Article
- Biochemical Characterization and Genome Analysis of Pseudomonas loganensis sp. nov., a Novel Endophytic Bacterium.MicrobiologyOpen · 2025Article
- Enhanced production of microbial levulinic acid through deletion of the levulinic acid transcriptional regulator (lvaR) in engineered Pseudomonas putida KT2440.Bioprocess and biosystems engineering · 2025Article
- EngineeringMetabolic engineering communications · 2025Article
- Model of metabolism and gene expression predicts proteome allocation in Pseudomonas putida.NPJ systems biology and applications · 2025Article
- Synthetic Biology in Natural Product Biosynthesis.Chemical reviews · 2025Review
- Bioprocess exploitation of microaerobic auto-induction using the example of rhamnolipid biosynthesis in Pseudomonas putida KT2440.Journal of biological engineering · 2025Article
- Unlocking the power of antimicrobial peptides: advances in production, optimization, and therapeutics.Frontiers in cellular and infection microbiology · 2025Review
- A dual-inducible control system for multistep biosynthetic pathways.Journal of biological engineering · 2024Article
- Strategy for Optimizing Vitamin B12 Production inMetabolites · 2024Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The biosynthesis of natural products by heterologous expression of biosynthetic pathways in amenable production strains enables biotechnological access to a variety of valuable compounds by conversion of renewable resources. Pseudomonas putida has emerged as a microbial laboratory work horse, with elaborated techniques for cultivation and genetic manipulation available. Beyond that, this bacterium offers several particular advantages with regard to natural product biosynthesis, notably a versatile intrinsic metabolism with diverse enzymatic capacities as well as an outstanding tolerance to xenobiotics. Therefore, it has been applied for recombinant biosynthesis of several valuable natural products. This review provides an overview of applications of P. putida as a host organism for the recombinant biosynthesis of such natural products, including rhamnolipids, terpenoids, polyketides and non-ribosomal peptides, and other amino acid-derived compounds. The focus is on de novo natural product synthesis from intrinsic building blocks by means of heterologous gene expression and strain engineering. Finally, the future potential of the bacterium as a chassis organism for synthetic microbiology is pointed out.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.